The IL-17A inhibitor, secukinumab, is in late-stage development forthe treatment of giant cell arteritis and polymyalgia rheumatica. https://t.co/JzzqS7bSjd https://t.co/9Qm0YsJmOL
Links:
The Impact of IL-17A Inhibition in Rheumatic and Musculoskeletal Diseases: Curr…
https://buff.ly/BoHdLFq
Apr-16-2025
